Jeffrey A. Lieberman, MD
- Lieber Professor of Psychiatry
- Lawrence C. Kolb Professor of Psychiatry
- Chair, Department of Psychiatry
- Attending Physician, NewYork-Presbyterian Hospital
Jeffrey A. Lieberman, MD, is the Lawrence C. Kolb Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons; Director, New York State Psychiatric Institute; and Psychiatrist-in-Chief, Columbia University Medical Center of the NewYork-Presbyterian Hospital. Dr. Lieberman’s work has advanced the understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.
He is the recipient of many national and international honors and awards, including the Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders, the Adolph Meyer Award from the American Psychiatric Association, the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmacology.
He is a member of numerous scientific organizations, including the National Academy of Sciences Institute of Medicine. He has authored more than 500 papers and articles published in the scientific literature and written and/or edited ten books on mental illness, psychopharmacology and psychiatry. In May 2012, Dr. Lieberman was installed as President-elect of the American Psychiatric Association (APA); he will serve as APA President from May 2013 to May 2014.
- NewYork-Presbyterian / Columbia University Irving Medical Center
- Behavioral Health Columbia University Employee Plan
Credentials & Experience
Education & Training
- George Washington University School of Medicine
- Residency: St Vincents Hospital NY NY
- Fellowship: Bronx Psychiatric Center
Dr. Lieberman’s research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations and has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH. He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.
Current clinical trials:
- Cognitive Remediation in Patients with Schizophrenia Stabilized on Lurasidone. Learn more.
- Evaluating Efficacy and Safety of RO4917838. Learn more.
- How a New Drug, DAR-0100A, Affects Memory, How You Think, And How You Make Decisions. Learn more.
- Testing Whether Investigational Drug RO4917838 is Safe and Can Improve Sub-Optimally Controlled Symptoms in Patients With Schizophrenia. Learn more.
- Studying metabolic changes in non-psychotic adults taking the antipsychotic medications Fanapt (iloperidone) or Zyprexa (olanzapine). Learn more.
THE NEUROBIOLOGY OF VIOLENCE IN A PSYCHOSIS RISK COHORT (Federal Gov)
Sep 1 2017 - May 31 2022
D-SERINE AUGMENTATION OF NEUROPLASTICITY-BASED AUDITORY LEARNING IN SCHIZOPHRENIA (Federal Gov)
Jan 16 2019 - Nov 30 2020
QUANTITATIVE ASSESSMENT AND COMPARISON OF MATABOLIC CHANGES IN NON-PSYCHOTIC ADULTS TAKING THE ANTIPSYCHOOTIC MEDICATIONS FANAPL (ILOPERIDONE) OR ZYPREXA (OLANZAPINE) OR PLACEBO (P&S Industry Clinical Trial)
Nov 13 2012 - Nov 13 2017
HUMAN TRIAL OF ALLOSTERIC MODULATOR ALPHA7 NICOTINIC RECEPTORS IN SCHIZOPHRENIA (Federal Gov)
Sep 1 2016 - Aug 31 2017
LONGITUDINAL IMAGING OF PATIENTS AT CLINICAL RISK FOR PSYCHOSIS. (Federal Gov)
Sep 22 2011 - May 31 2016
BH4 TREATMENT IN SCHIZOPHRENIA (Private)
Feb 15 2011 - Nov 30 2015
A D1 AGONIST FOR WORKING MEMORY ENHANCEMENT IN THE SCHIZOPHRENIA SPECTRUM (Federal Gov)
Apr 1 2013 - Feb 28 2014
RECOVERY AFTER AN INITIAL SCHIZOPHRENIC EPISODE (RAISE) (Federal Gov)
Jul 13 2009 - Dec 31 2013
2/2 A GENOME-WIDE ASSOCIATION STUDY TO DETECT GENETIC VARIATION FOR SCHIZOPHRENIA (Federal Gov)
Jun 1 2010 - May 31 2012
CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH S CHIZOPHRENIA: SWITCHICLINICAL MANAGEMENT OF METO ARIPIPRAZOL (Private)
Aug 1 2006 - Dec 31 2010